Hamilton Lane Incorporated is an investment firm specializing in direct and fund of fund investments. It provides following services: separate accounts (customized to each individual client and structured as single client vehicles); specialized strategies (fund-of-funds, secondaries, co-investments, taft-hartley, distribution management); advisory relationships (including due diligence, strategic portfolio planning, monitoring and reporting services); and reporting and analytics solutions. For direct investments, the firm invests in early, mid and late venture, mature companies, growth equity, emerging growth, distressed debt, later stage, turnarounds, bridge financing, mezzanine financing, and buyouts in middle market companies. For fund of fund investments, it invests in mezzanine, venture capital, private equity, turnaround, secondary investments, real estate, and special situation funds. The firm invests in real estate investments. It also invest in technology, healthcare, education, natural resources, energy and essential consumer goods sectors, cleantech, and environment, community development, and financial empowerment. It invests in private equity markets in North America, Latin America, United States, Western Europe, Middle East, Africa, United Kingdom, Asia, Japan, and Australia. The firm prefer to invest $1 million to $100 million in companies. It prefers to have majority stake in companies. Hamilton Lane Incorporated was founded in 1991 and is based in Conshohocken, Pennsylvania with additional offices across Europe, North America, and Asia.
IPO Year: 2017
Exchange: NASDAQ
Website: hamiltonlane.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/16/2026 | $166.00 | Neutral → Overweight | Analyst |
| 12/11/2025 | $166.00 | Buy | UBS |
| 11/6/2025 | $165.00 | Neutral → Buy | Goldman |
| 10/14/2025 | $181.00 | Perform → Outperform | Oppenheimer |
| 10/13/2025 | $150.00 | Mkt Perform → Outperform | Keefe Bruyette |
| 10/3/2025 | $150.00 | Outperform | BMO Capital Markets |
| 9/18/2025 | $162.00 | Sell → Neutral | Goldman |
| 5/15/2025 | Outperform → Perform | Oppenheimer | |
| 1/21/2025 | $186.00 | Perform → Outperform | Oppenheimer |
| 1/6/2025 | $139.00 | Neutral → Sell | Goldman |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Analyst upgraded Hamilton Lane from Neutral to Overweight and set a new price target of $166.00
UBS resumed coverage of Hamilton Lane with a rating of Buy and set a new price target of $166.00
Goldman upgraded Hamilton Lane from Neutral to Buy and set a new price target of $165.00
Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $181.00
Keefe Bruyette upgraded Hamilton Lane from Mkt Perform to Outperform and set a new price target of $150.00
BMO Capital Markets initiated coverage of Hamilton Lane with a rating of Outperform and set a new price target of $150.00
Goldman upgraded Hamilton Lane from Sell to Neutral and set a new price target of $162.00
Oppenheimer downgraded Hamilton Lane from Outperform to Perform
Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $186.00
Goldman downgraded Hamilton Lane from Neutral to Sell and set a new price target of $139.00
SCHEDULE 13D/A - Hamilton Lane INC (0001433642) (Subject)
10-K - Hamilton Lane INC (0001433642) (Filer)
8-K - Hamilton Lane INC (0001433642) (Filer)
SCHEDULE 13G/A - Hamilton Lane INC (0001433642) (Subject)
SCHEDULE 13G/A - Hamilton Lane INC (0001433642) (Subject)
8-K - Hamilton Lane INC (0001433642) (Filer)
10-Q - Hamilton Lane INC (0001433642) (Filer)
8-K - Hamilton Lane INC (0001433642) (Filer)
10-Q - Hamilton Lane INC (0001433642) (Filer)
8-K - Hamilton Lane INC (0001433642) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
Fastest customizable press release news feed in the world
CONSHOHOCKEN, Pa., May 21, 2026 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth quarter and full fiscal year ended March 31, 2026. The Company issued a full detailed presentation of its fourth quarter and full fiscal year 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/.DividendHamilton Lane has declared a quarterly dividend of $0.60 per share of Class A common stock to record holders at the close of business on June 18, 2026 that will be paid on July 7, 2026. The target full-year dividend of $2.40 represents a 11% increase from t
— Proven biopharmaceutical executive to lead commercial strategy as Cosette scales its branded pharmaceutical platform and advances its next phase of growth — Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions – including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible
MidOcean Partners ("MidOcean"), a premier New York-based alternative asset manager specializing in middle-market private equity, alternative credit, and structured equity, today announced the closing of a single-asset continuation vehicle for Cloyes Gear and Products, Inc. ("Cloyes" or the "Company"), the North American leader and global designer, developer, manufacturer, and distributor of mission-critical timing drive systems and components for the automotive aftermarket. The continuation vehicle secured approximately $300 million in commitments, with funds managed by Hamilton Lane (NASDAQ:HLNE) serving as sole lead investor. In connection with the continuation vehicle, MidOcean-managed
-- Experienced life sciences executive to lead legal, compliance, and governance as Cosette scales its platform following recent acquisitions and continued growth momentum -- Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today that it has appointed Erika Tooman as Senior Vice President and General Counsel, strengthening the company's executive leadership team as it advances its long‑term growth, portfolio expansion, and value‑creation strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429022652/en/ Erika brings more than two decades of experience guiding pharmaceutica
MONTREAL, April 29, 2026 /CNW/ - Power Sustainable Energy Infrastructure ("PSEI"), the renewable energy infrastructure platform of Power Sustainable, today announced it completed the sale of a 49.9% interest in Big Sky Wind, a 240 MW operating wind facility located in Illinois, to funds managed by Hamilton Lane (NASDAQ:HLNE) and GCM Grosvenor, two leading global private markets investment firms. PSEI will retain a majority interest in the asset and continue to oversee its operations. The transaction reflects PSEI's strategy of partnering with long-term institutional investors while actively recycling capital to fund new investments across its portfolio."We are pleased to partner with Hamilto
CONSHOHOCKEN, Pa., April 23, 2026 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2026 before the market opens on Thursday, May 21, 2026. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on May 21 to discuss the results for the fourth fiscal quarter and full fiscal year. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here at least 15 minutes prior to the start of the call. This f
The Hamilton Lane Credit Income Fund is now available to institutional and private wealth investors via the interval fund structureThe firm's Private Infrastructure Fund is now offered in an interval fund structure and is also available in a tokenized format through Republic's digital platformCONSHOHOCKEN, Pa., April 22, 2026 /PRNewswire/ -- Hamilton Lane (NASDAQ:HLNE) today announced the launch of the Hamilton Lane Credit Income Fund ("HLCIF") and the conversion of the Hamilton Lane Private Infrastructure Fund ("HLPIF") to an interval fund structure. Structured as interval funds, HLCIF and HLPIF are designed to offer institutional and private wealth investors in the U.S. access to private m
Over 25 promotions and appointments to Managing Director and Principal reflect the firm's continued growth and expansion of its product offerings and client and investment teamsCONSHOHOCKEN, Pa., April 20, 2026 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (NASDAQ:HLNE) today announced senior promotions and new appointments across its Investment, Client Solutions, Portfolio Management, Legal, Finance and Operations Teams. The firm recognized the promotions of the following individuals to Managing Director:Anastasia Di Carlo, Client SolutionsBrian Reilly, Taft-HartleyEmily Lozada, Investment LegalJan Verstraete, Secondary InvestmentsKaylin Liu, Fund Ac
-- Adds Portfolio of Branded Products with $48.9 million in 2025 Net Sales and an Established Commercial Presence -- -- SYMPAZAN® Establishes a Neurology Rare Disease Footprint within Cosette -- -- Additional Brands include INDOCIN®, SPRIX®, ZIPSOR®, CAMBIA®, and OTREXUP® -- Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sales and distribution rights for a portfolio of seven branded products from Assertio Holdings, Inc. (NASDAQ:ASRT). The acquisition expands Cosette's branded portfolio and adds the U.S. rights to SYMPAZAN®, a growing, patent-protected asset, further advanc
$425 Million Debt Facility, Expandable to $585M, Funds Continued Fiber Network Expansion, Fiber-to-the-Premise Market Growth and Complementary AcquisitionsBOULDER, Colo., April 6, 2026 /PRNewswire/ -- VFN Holdings, Inc. (Vero), a nationwide fiber infrastructure provider serving wholesale, technology, enterprise and retail internet customers, today announced the successful expansion of its existing credit facility to $425 million of committed capital. The facility includes an accordion feature providing up to $585 million of total capacity and was jointly arranged by Hancock Whitney Bank, Texas Capital and J.P. Morgan. Vero was able to complete this facility expansion exclusively with increas
Live Leadership Updates
— Proven biopharmaceutical executive to lead commercial strategy as Cosette scales its branded pharmaceutical platform and advances its next phase of growth — Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions – including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible
-- Experienced life sciences executive to lead legal, compliance, and governance as Cosette scales its platform following recent acquisitions and continued growth momentum -- Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today that it has appointed Erika Tooman as Senior Vice President and General Counsel, strengthening the company's executive leadership team as it advances its long‑term growth, portfolio expansion, and value‑creation strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429022652/en/ Erika brings more than two decades of experience guiding pharmaceutica
Expanded institutional participation underscores growing demand for private market opportunities and standardized operating infrastructureNEW YORK, March 9, 2026 /PRNewswire/ -- Corastone, the hyperscaler for private-market investing, today announced Fidelity Investments, Future Standard, and Hamilton Lane (NASDAQ:HLNE) as investors in Corastone and its alternative-investing operating platform. This growing institutional participation builds on Corastone's recent platform launch and comes as demand for private markets investments expands across investor types. As global private
Appointment underscores firm's commitment to expanding access to private markets for individual investors in JapanTOKYO, March 1, 2026 /PRNewswire/ -- Hamilton Lane (NASDAQ:HLNE), a leading global private markets investment firm, announced the appointment of Mika Tashiro as Head of Private Wealth Solutions in Japan. In this newly-created role, Tashiro will be responsible for leading Hamilton Lane's private wealth strategy in the country, deepening relationships with leading wealth management firms and financial institutions and expanding access to the firm's global evergreen platform for Japanese investors. In her role, Tashiro is focused on expanding Hamilton Lane's footprint across Japan's
CONSHOHOCKEN, Pa. and NEW YORK, Nov. 3, 2025 /PRNewswire/ -- Leading private markets firm Hamilton Lane (NASDAQ:HLNE) and The Guardian Life Insurance Company of America® ("Guardian"), one of the nation's largest life insurers and a leading provider of employee benefits, today announced an innovative, long-term strategic partnership. Through this partnership, Hamilton Lane will manage Guardian's existing private equity portfolio of nearly $5 billion. Guardian will also commit to invest approximately $500 million per year in private equity for the next 10 years through Hamilton Lane. This commitment maintains Guardian's typical annual contribution to the asset class and supports its general a
-- Experienced Industry Leader to drive Cosette's Best-in-Class Quality Organization and facilitate Regulatory Approvals -- Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630266171/en/Jeff Neubig, VP, Quality & Regulatory Affairs, Cosette Pharmaceuticals In this critical role, Jeff will lead Cosette's best-in-class quality and regulatory affairs organizations, maintaining the company's rigorous quality standards and further establishing Co
Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova's board, and the successful completion of a new round of growth equity capital. These developments support Grenova's strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company's future. "I
Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/Senior Vice President, Operations (Photo
Experienced commercial leader joins Cosette to drive the next phase of growth and transformation Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Brad Leonard as Vice President, Generics Commercial Operations. In this role, Brad will spearhead Cosette's generics business, including Generics Sales, Marketing/Pricing, Customer Service, and Demand Planning, as the company continues its expansion in these markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250203104224/en/Brad Leonard, Vice President, Generics Commercial Operations (Photo: Business Wire) "Cosette is
The firm broadens its co-investment capabilities with the additions of five senior team membersGlobal appointments highlight continued growth within the asset class and historic success of the firm's Direct Equity platform, which stands at $15.3 billion in AUM* CONSHOHOCKEN, Pa., Nov. 12, 2024 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (NASDAQ:HLNE) today announced the expansion of its Direct Equity Investment Team, with the appointment of five new senior team members based in North America and Europe to support the continued growth of the asset class.
Live finance-specific insights
CONSHOHOCKEN, Pa., May 21, 2026 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth quarter and full fiscal year ended March 31, 2026. The Company issued a full detailed presentation of its fourth quarter and full fiscal year 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/.DividendHamilton Lane has declared a quarterly dividend of $0.60 per share of Class A common stock to record holders at the close of business on June 18, 2026 that will be paid on July 7, 2026. The target full-year dividend of $2.40 represents a 11% increase from t
CONSHOHOCKEN, Pa., April 23, 2026 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2026 before the market opens on Thursday, May 21, 2026. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on May 21 to discuss the results for the fourth fiscal quarter and full fiscal year. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here at least 15 minutes prior to the start of the call. This f
CONSHOHOCKEN, Pa. and NEW YORK, March 17, 2026 /PRNewswire/ -- Hamilton Lane (NASDAQ:HLNE), a leading global private markets investment firm, today announced a strategic investment in Republic, a leading on-chain global investment platform, reinforcing the firms' shared commitment to expanding retail investor access to institutional-quality private market funds. The investment builds on the existing partnership between Hamilton Lane and Republic, and underscores Hamilton Lane's long-term strategy to modernize and expand access to private markets. Together, the firms are enabling broader participation in the private markets asset class, which has historically been limited to institutions and
CONSHOHOCKEN, Penn., Feb. 3, 2026 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the third fiscal quarter ended December 31, 2025. The Company issued a full detailed presentation of its third quarter fiscal 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/. Dividend Hamilton Lane has declared a quarterly dividend of $0.54 per share of Class A common stock to record holders at the close of business on March 20, 2026 that will be paid on April 6, 2026. The target full-year dividend of $2.16 represents a 10% increase from the prior fiscal year
Inaugural report empowers individuals to navigate uncertainty, identify emerging opportunities, and plan holistically across their financial lives NEW YORK, Jan. 20, 2026 /PRNewswire/ -- As headlines and data often paint a conflicting economic picture, The Guardian Life Insurance Company of America® (Guardian) has issued Guardian Wealth Insights: The Year Ahead, an outlook designed to help Americans make sense of the financial opportunities and challenges in 2026. Read Guardian Wealth Insights: The Year Ahead here From navigating megatrends like inflation and regulatory change
CONSHOHOCKEN, Pa., Jan. 13, 2026 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the third fiscal quarter ended December 31, 2025 before the market opens on Tuesday, February 3, 2026. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website at https://shareholders.hamiltonlane.com/. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on February 3 to discuss the results for the third fiscal quarter. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here (https://shareholders.hamiltonlane.com/) at least
CONSHOHOCKEN, Pa., Nov. 4, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the second fiscal quarter ended September 30, 2025. The Company issued a full detailed presentation of its second quarter fiscal 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/. Dividend Hamilton Lane has declared a quarterly dividend of $0.54 per share of Class A common stock to record holders at the close of business on December 19, 2025 that will be paid on January 7, 2026. The target full-year dividend of $2.16 represents a 10% increase from the prior fisca
- KAIO has been leading the tokenization of major institutional funds, expanding crypto-native access to regulated money markets and alternative investment strategies - The tokenization of Hamilton Lane SCOPE Fund on Sei's DeFi optimized design is expected to enhance accessibility for the fund's investors ABU DHABI, UAE, Oct. 15, 2025 /PRNewswire/ -- KAIO, the leading fully onchain infrastructure for regulated real-world assets (RWAs), today announced the expansion of its tokenized fund offerings on the Sei Network by bringing access to Hamilton Lane's (NASDAQ:HLNE) Senior Credit Opportunities Fund ("SCOPE") onchain, via HL SCOPE Access Fund1, for institutional and accredited inv
CONSHOHOCKEN, Pa., Oct. 14, 2025 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the second fiscal quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website at https://shareholders.hamiltonlane.com/. Hamilton Lane will host a conference call via webcast at 10:00 a.m. ET on November 4 to discuss the results for the second fiscal quarter. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here (https://shareholders.hamiltonlane.com/) at lea
Backed by a new funding round led by S&P Global, Novata is defining the next era of sustainability data for private markets Novata, a leading sustainability data management platform for private markets, today announced the acquisition of Atlas Metrics, a top European sustainability performance and reporting platform. This strategic move expands Novata's global reach and unites two complementary companies to meet the growing demand from investors and corporates for trusted, efficient, and scalable sustainability data solutions. Together, Novata and Atlas Metrics now supports more than 400 clients and 13K+ companies worldwide, equipping investors, banks, and corporates with the tools th
This live feed shows all institutional transactions in real time.
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13D/A - Hamilton Lane INC (0001433642) (Subject)
SC 13D/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13D/A - Hamilton Lane INC (0001433642) (Subject)